NRX Pharmaceuticals Files 2023 Annual Report on Form 10-K

TL;DR

<b>NRX Pharmaceuticals filed its 2023 10-K, detailing financial reporting and fair value measurements.</b>

AI Summary

NRX Pharmaceuticals, Inc. (NRXPW) filed a Annual Report (10-K) with the SEC on March 29, 2024. NRX Pharmaceuticals, Inc. filed its 2023 Form 10-K on March 29, 2024. The company was formerly known as Big Rock Partners Acquisition Corp. and changed its name on October 12, 2017. The fiscal year end for NRX Pharmaceuticals is December 31. The filing includes details on fair value measurements and inputs for Level 3 fair value measurements as of December 31, 2023. Specific inputs mentioned include share price, risk-free interest rate, price volatility, exercise price, and expected dividend rate for various warrant agreements in 2023.

Why It Matters

For investors and stakeholders tracking NRX Pharmaceuticals, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of NRX Pharmaceuticals' financial performance and position for the fiscal year ended December 31, 2023. The detailed fair value measurements offer insight into the valuation of the company's financial instruments, particularly warrants, which are crucial for understanding potential dilution and financial obligations.

Risk Assessment

Risk Level: — NRX Pharmaceuticals, Inc. shows moderate risk based on this filing. The company's financial health and future prospects are subject to the inherent risks of pharmaceutical development, including regulatory approvals and market acceptance, which are not detailed in this specific filing excerpt.

Analyst Insight

Investors should review the full 10-K to understand the company's financial performance, risk factors, and strategic outlook for 2024.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-03-29 — Filing Date (10-K submission date)
• 0001719406 — Central Index Key (Company identifier)

Key Players & Entities

• NRX Pharmaceuticals, Inc. (company) — Filer name
• Big Rock Partners Acquisition Corp. (company) — Former company name
• 2023-12-31 (date) — Fiscal year end
• 2024-03-29 (date) — Filing date
• August Investors (company) — Warrant agreement party
• June Placement Agent Warrants (other) — Warrant type
• June Investor Amended Warrants (other) — Warrant type

FAQ

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-03-29: 10-K Filing Date — Date NRX Pharmaceuticals submitted its annual report.

Glossary

10-K

An annual report required by the U.S. Securities and Exchange Commission (SEC), which gives a comprehensive summary of a company's financial performance. (This filing provides the official annual financial overview for NRX Pharmaceuticals.)

Fair Value Measurements

The process of determining the price at which an asset would be sold or a liability would be transferred in an orderly transaction between market participants. (Crucial for understanding the valuation of financial instruments like warrants held by NRX Pharmaceuticals.)

Level 3 Fair Value Inputs

Unobservable inputs used in fair value measurements, based on the company's own assumptions and models. (Indicates that NRX Pharmaceuticals uses its own estimations for valuing certain assets/liabilities, requiring careful scrutiny.)

Key Financial Figures

• $0.001 — h registered: Common Stock, par value $0.001 per share NRXP The Nasdaq Stock Marke
• $4 billion — pment partnership with Alvogen, Inc., a $4 billion US-based pharmaceutical company and Lot
• $330 million — ship provides for up to an aggregate of $330 million in commercial stage milestone payments
• $9.2 million — n the corporate indebtedness and raised $9.2 million in new capital during FY 2023 with $7.8
• $7.8 million — lion in new capital during FY 2023 with $7.8 million of additions to working capital during
• $0.40 — ment in negative Earnings per Share to ($0.40) in FY 2023 vs ($0.60) in prior 12 mont
• $0.60 — ngs per Share to ($0.40) in FY 2023 vs ($0.60) in prior 12 month period. Management p
• $60 million — has received term sheets for more than $60 million in funding from new investors upon publ
• $30 million — elop Aviptadil and to pay NRx more than $30 million in royalties and milestones from its fu
• $0 — rice for each share of Common Stock was $0.30, and the Underwriters purchased the
• $0.276 — price for each share of Common Stock of $0.276. On February 28, 2024, the February 202
• $1.5 m — 2024 Public Offering were approximately $1.5 million, before deducting underwriting di
• $0.33 — ) sold, at an initial exercise price of $0.33 per share, subject to certain adjustmen
• $0.38 — ts "February Warrants") at a price of $0.38 per share of Common Stock and accompany
• $1.0 million — 24 Private Placement were approximately $1.0 million. NRx Products in Development NRX-101

Filing Documents

• nrxp-20231231x10k.htm (10-K) — 3245KB
• nrxp-20231231xex4d8.htm (EX-4.8) — 23KB
• nrxp-20231231xex4d9.htm (EX-4.9) — 63KB
• nrxp-20231231xex10d55.htm (EX-10.55) — 43KB
• nrxp-20231231xex10d60.htm (EX-10.60) — 54KB
• nrxp-20231231xex10d64.htm (EX-10.64) — 244KB
• nrxp-20231231xex10d66.htm (EX-10.66) — 108KB
• nrxp-20231231xex23d1.htm (EX-23.1) — 5KB
• nrxp-20231231xex31d1.htm (EX-31.1) — 12KB
• nrxp-20231231xex31d2.htm (EX-31.2) — 12KB
• nrxp-20231231xex32d1.htm (EX-32.1) — 6KB
• nrxp-20231231xex32d2.htm (EX-32.2) — 6KB
• nrxp-20231231xex97d1.htm (EX-97.1) — 42KB
• nrxp-20231231x10k001.jpg (GRAPHIC) — 18KB
• nrxp-20231231x10k002.jpg (GRAPHIC) — 16KB
• nrxp-20231231x10k003.jpg (GRAPHIC) — 60KB
• nrxp-20231231x10k004.jpg (GRAPHIC) — 16KB
• nrxp-20231231x10k005.jpg (GRAPHIC) — 21KB
• nrxp-20231231x10k006.jpg (GRAPHIC) — 38KB
• nrxp-20231231x10k007.jpg (GRAPHIC) — 7KB
• nrxp-20231231x10k008.jpg (GRAPHIC) — 18KB
• nrxp-20231231x10k009.jpg (GRAPHIC) — 19KB
• nrxp-20231231x10k010.jpg (GRAPHIC) — 19KB
• nrxp-20231231x10k011.jpg (GRAPHIC) — 49KB
• nrxp-20231231x10k012.jpg (GRAPHIC) — 13KB
• 0001558370-24-004396.txt (&nbsp;) — 10435KB
• nrxp-20231231.xsd (EX-101.SCH) — 62KB
• nrxp-20231231_cal.xml (EX-101.CAL) — 45KB
• nrxp-20231231_def.xml (EX-101.DEF) — 243KB
• nrxp-20231231_lab.xml (EX-101.LAB) — 417KB
• nrxp-20231231_pre.xml (EX-101.PRE) — 403KB
• nrxp-20231231x10k_htm.xml (XML) — 1059KB

Business

Item 1. Business 4

Risk Factors

Item 1A. Risk Factors 46

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 84

Cybersecurity

Item 1C. Cybersecurity 85

Properties

Item 2. Properties 85

Legal Proceedings

Item 3. Legal Proceedings 86

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 86 Part II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchase of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchase of Equity Securities 87

[Reserved]

Item 6. [Reserved] 88

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 89

Quantitative and Qualitative Disclosure about Market Risk

Item 7A. Quantitative and Qualitative Disclosure about Market Risk 102

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 102

Changes in Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in Disagreements with Accountants on Accounting and Financial Disclosure 145

Controls and Procedures

Item 9A. Controls and Procedures 145

Other Information

Item 9B. Other Information 146 Part III.

Directors, Executive Officers, and Corporate Governance

Item 10. Directors, Executive Officers, and Corporate Governance 147

Executive Compensation

Item 11. Executive Compensation 147

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 147

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 147

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services 147 Part IV.

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 148 Table of Contents CAUTIONARY STATEMENT This document and the information incorporated by reference herein include "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Company's strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Company's management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "would," "seek," "plan," "intend," "shall," and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. These forward- looking statements are, by their nature, subject to significant risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. These risks and uncertainties include, but are not limited to, our relatively limited operating history; our ability to expand, retain and motivate our employees and manage our growth; risks associated with general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Company's ability to accurately predict future m

Business

Item 1. Business Company Overview and History NRx is a clinical-stage bio-pharmaceutical company which develops and will distribute, through its wholly-owned operating subsidiaries, NeuroRx, Inc., ("NeuroRx") and HOPE Therapeutics, Inc. ("HOPE"), novel therapeutics for the treatment of central nervous system disorders including suicidal depression, chronic pain, and PTSD. NeuroRx is organized as a traditional Research and Development ("R&D") company, whereas HOPE is organized as a Specialty Pharmaceutical (SpecPharma) company intended to distribute ketamine and other therapeutic options to clinics that serve patients with suicidal depression and PTSD. The 2023 fiscal year was one of extraordinary growth and transition for NRx. During the year the Company restructured its management to overcome challenges in capital formation, clinical trial enrollment, and corporate growth, in a manner that resulted in demonstrable milestones for 2023 and a company that we believe to be poised for growth in 2024. Those milestones achieved in 2023 and through the date of this filing include: 1. Recruitment of a new management team under the leadership of Jonathan Javitt, MD, MPH (the Company's Founder and Chairman) and Stephen Willard, JD, (CEO and Director), comprised of individuals with demonstrated success in the design, recruitment, and analysis of clinical-stage drug development, together with demonstrated commercial success in the marketing and sales of commercial stage pharmaceuticals. This management team includes a new Chief Financial Officer, Chief Business Officer, Director of Clinical Research, Head of Regulatory Affairs, Head of Scientific Affairs, and a new Chief Medical Lead for urology. 2. Establishment of a drug development partnership with Alvogen, Inc., a $4 billion US-based pharmaceutical company and Lotus Pharmaceutical Company, LTD (1975.TW), an Asia Pacific-based pharmaceutical company to jointly develop NRX-101 for the treatment of suicidal bipolar de

View Full Filing

View this 10-K filing on SEC EDGAR